NCT05655507View on ClinicalTrials.gov

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

Zuranolone

Administered as capsules

Trial Locations (4)

30030

Sage Investigational Site, Decatur

30331

Sage Investigational Site, Atlanta

39232

Sage Investigational Site, Flowood

45219

Sage Investigational Site, Cincinnati

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT05655507 - Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD) | Biotech Hunter | Biotech Hunter